Trial reportSchizophrenia research2012
Rimonabant for neurocognition in schizophrenia: a 16-week double blind randomized placebo controlled trial.
Trial report in Schizophrenia research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 52 citations in OpenAlex.
- Cannabinoid Receptors: An Update on Cell Signaling, Pathophysiological Roles and Therapeutic Opportunities in Neurological, Cardiovascular, and Inflammatory Diseases.International journal of molecular sciences · 2020Pooled it
- How effective and safe is medical cannabis as a treatment of mental disorders? A systematic review.European archives of psychiatry and clinical neuroscience · 2019Pooled it
- Overview of Novel Antipsychotic Drugs: State of the Art, New Mechanisms, and Clinical Aspects of Promising Compounds.Biomedicines · 2025Review
- Network-based drug repurposing for schizophrenia.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024Article
- Cannabidiol (CBD) as a novel treatment in the early phases of psychosis.Psychopharmacology · 2022Review
- Are There Therapeutic Benefits of Cannabinoid Products in Adult Mental Illness?Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2021Article
- From the Clinic to the Laboratory, and Back Again: Investigations on Cannabinoids and Endocannabinoid System Modulators for Treating Schizophrenia.Frontiers in psychiatry · 2021Review
- Decision Making and Impulsivity in Young Adult Cannabis Users.Frontiers in psychology · 2021Article
- Therapeutic potential and safety considerations for the clinical use of synthetic cannabinoids.Pharmacology, biochemistry, and behavior · 2020Review
- Effects of combined 5-HTPsychopharmacology · 2020Article
- Kynurenines and the Endocannabinoid System in Schizophrenia: Common Points and Potential Interactions.Molecules (Basel, Switzerland) · 2019Review
- Role of the Endocannabinoid System in the Pathophysiology of Schizophrenia: Implications for Pharmacological Intervention.CNS drugs · 2018Review
- Differential effects of cannabinoid CB1 inverse agonists and antagonists on impulsivity in male Sprague Dawley rats: identification of a possibly clinically relevant vulnerability involving the serotonin 5HTPsychopharmacology · 2017Article
- Cannabinoids and Schizophrenia: Risks and Therapeutic Potential.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2015Review
- Neurology issues in schizophrenia.Current psychiatry reports · 2015Review
- Psychopharmacological treatment of neurocognitive deficits in people with schizophrenia: a review of old and new targets.CNS drugs · 2014Review
- Psychiatric symptom differences in people with schizophrenia associated with substantial lifetime substance use but no current substance use disorder.Schizophrenia research · 2014Article
- Peripheral endocannabinoid system dysregulation in first-episode psychosis.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2013Article
- The potential role of dopamine D₃ receptor neurotransmission in cognition.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology · 2013Review
- Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.Molecular psychiatry · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
Abstract
objectiveTo examine the effect of rimonabant on neurocognitive impairments in people with schizophrenia.
methodsParticipants entered a 16-week double-blind, placebo-controlled, randomized clinical trial. A neurocognitive battery was administered at baseline and end of study.
resultsIn comparison to rimonabant (20mg/day), placebo-treated participants exhibited a significant improvement on the Repeatable Battery for the Assessment of Neuropsychological Status total score. In contrast, rimonabant was associated with significant improvement on a probabilistic learning task. There were no other significant treatment effects.
conclusionsRimonabant did not improve global cognitive functioning, but did improve a specific learning deficit based on response to positive feedback.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.